Michal Mrug
Nephrology · Birmingham, ALNPI 1952331332
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $70,665 of the $73,016 with a category attached, or 96.8%. 7 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 53.3% of the total. Reporting peaked in 2024 at $17,862 and has fallen 89.1% since, to $1,940 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 40 payments — averaging $1825.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$39K
- Vertex$17K
- Sanofi$11K
- Sanofi-aventis U.S. LLC$3K
- Otsuka America Pharmaceutical, Inc.$2K
- ZOLL Medical Corporation$1K
- plus $533 from 1 others
Across 28 payments — averaging $25,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$314K
- Vertex$218K
- Sanofi$188K
- AbbVie$3K
- Janssen Research & Development, LLC$3K
What the payments were for
- Consulting fees$70,66597%
- Travel & lodging$2,0293%
- Food & beverage$3210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 17 | $38,924 |
| Vertex | 10 | $16,702 |
| Sanofi | 3 | $10,777 |
| Sanofi-aventis U.S. LLC | 3 | $3,153 |
| Otsuka America Pharmaceutical, Inc. | 4 | $1,859 |
| ZOLL Medical Corporation | 2 | $1,067 |
| Insmed, Inc. | 1 | $533 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOLVAPTAN$14,032
- JYNARQUE$5,799
- GZ402671$1,213
- Defibrillator$1,067
How this compares
$73,016 in reported general payments places this provider in the 95th percentile of 164 nephrology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 15 | $26,400 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Vineeta KumarBirmingham$59K
- Ashita TolwaniBirmingham$56K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
- Timmy LeeBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.